только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 11 / 16
Страница 1 / 1

Список литературы

  1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int, Suppl 2012;2:139-274. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2012-GN- Guideline-English.pdf
  2. Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997;30(5):621-31. doi: 10.1016/s0272-6386(97)90485-6
  3. Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996;27:647-51. doi: 10.1016/s0272- 6386(96)90098-0
  4. Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 2017;12(3):502-517. doi: 10.2215/CJN.05960616
  5. Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol 2015;11(2):76-87. doi: 10.1038/nrneph.2014.216
  6. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010;5(11):2115-21. doi: 10.2215/CJN.03800609
  7. Candelier JJ, Lorenzo HK. Idiopathic nephrotic syndrome and serum permeability factors: a molecular jigsaw puzzle. Cell Tissue Res 2020;379(2):231-243. doi: 10.1007/s00441-019-03147-y
  8. Abdi R, Dong VM, Rubel JR et al. Correlation between glomerular size and long-term renal function in patients with substantial loss of renal mass. J Urol 2003;170(1):42-4. doi: 10.1097/01.ju.0000069821.97385.6b
  9. D'Agati VD, Chagnac A, de Vries APJ et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol 2016;12(8):453-71. doi: 10.1038/nrneph.2016.75
  10. Cunningham EE, Zielezny MA, Venuto RC. Heroin-associated nephropathy. A nationwide problem. JAMA 1983;250(21):2935-6
  11. Barri YM, Munshi NC, Sukumalchantra S et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004;65(2):634-41. doi: 10.1111/j.1523-1755.2004.00426.x
  12. Dressler D, Wright JR, Houghton JB, Kalra PA. Another case of focal segmental glomerulosclerosis in an acutely uraemic patient following interferon therapy. Nephrol Dial Transplant 1999;14(8):2049-50. doi: 10.1093/ndt/14.8.2049
  13. Herlitz LC, Markowitz GS, Farris AB et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol 2010;21(1):163-72. doi: 10.1681/ASN.2009040450
  14. Santella RN, Rimmer JM, MacPherson BR. Focal segmental glomerulosclerosis in patients receiving lithium carbonate. Am J Med 1988;84(5):951-4. doi: 10.1016/0002- 9343(88)90077-0
  15. Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis 2013;61(5):778-81. doi: 10.1053/j.ajkd.2012.08.048
  16. Meehan SM, Pascual M, Williams WW et al. De novo collapsing glomerulopathy in renal allografts. Transplantation 1998;65(9):1192-7. doi: 10.1097/00007890-199805150-00009
  17. Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005;353(19):2088-9. doi: 10.1056/NEJM200511103531922…..
  18. Malone AF, Phelan PJ, Hall G et al. Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. Kidney Int 2014;86(6):1253-9. doi: 10.1038/ki.2014.305
  19. Hinkes BG, Mucha B, Vlangos CN et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007;119(4):e907-19. doi: 10.1542/peds.2006-2164
  20. Boyer O, Benoit G, Gribouval O et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol 2011;22(2):239-45. doi: 10.1681/ASN.2010050518
  21. Rivera F, López-Gómez JM, Pérez-García R, Spanish Registry of Glomerulonephritis. Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004;66(3):898- 904. doi: 10.1111/j.1523-1755.2004.00833.x
  22. Hommos MS, De Vriese AS, Alexander MP et al. The incidence of primary vs secondary focal segmental glomerulosclerosis: a clinicopathologic study. Mayo Clin Proc 2017; 92(12):1772-1781. doi: 10.1016/j.mayocp.2017.09.011
  23. Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004;44(5):815-25
  24. Yao T, Udwan K, John R et al. Integration of Genetic Testing and Pathology for the Diagnosis of Adults with FSGS. Clin J Am Soc Nephrol 2019;14(2):213-223. doi: 10.2215/CJN.08750718
  25. Хроническая болезнь почек (ХБП). Клинические рекомендации. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf
  26. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604-12. doi: 10.7326/0003-4819-150-9- 200905050-00006
  27. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010;55(4):622-7. doi: 10.1053/j.ajkd.2010.02.337
  28. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004;43(2):368-82. doi: 10.1053/j.ajkd.2003.10.024
  29. De Vriese AS, Sethi S, Nath KA et al. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol 2018; 29(3):759-774. doi: 10.1681/ASN.2017090958
  30. Rao TKS. Renal complications in HIV disease. Med Clin North Am 1996;80(6):1437-51
  31. Winston JA, Burns GC, Klotman PE. The human immunodeficiency virus (HIV) epidemic and HIV-associated nephropathy. Semin Nephrol 1998;18(4):373-7
  32. Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002;62(6):2301-10. doi: 10.1046/j.1523-1755.2002.00674.x
  33. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15(8):2169-77. doi: 10.1097/01.ASN.0000135051.62500.97
  34. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995;25(4):534- 42. doi: 10.1016/0272-6386(95)90120-5
  35. Thomas DB, Franceschini N, Hogan SL et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006;69(5):920-6. doi: 10.1038/sj.ki.5000160
  36. Sethi S, Zand L, Nasr SH et al. Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations. Clin Kidney J 2014; 7(6):531-7. doi: 10.1093/ckj/sfu100
  37. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59(4):1498-509. doi: 10.1046/j.1523- 1755.2001.0590041498.x
  38. Praga M, Morales E, Herrero JC et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 1999;33(1):52-8. doi: 10.1016/s0272-6386(99)70257-x
  39. Chagnac A, Weinstein T, Herman M et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003;14(6):1480-6. doi: 10.1097/01.asn.0000068462.38661.89
  40. Lepori N, Zand L, Sethi S et al. Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. Clin Kidney J 2018;11(2):179-190. doi: 10.1093/ckj/sfx143
  41. Caridi G, Bertelli R, Carrea A et al. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol 2001;12(12):2742-6
  42. Ashraf S, Kudo H, Rao J et al. Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment. Nat Commun 2018;17;9(1):1960. doi: 10.1038/s41467- 018-04193-w
  43. Нефрология. Клинические рекомендации. По ред. Шилов ЕМ, Смирнов АВ, Козловская НЛ. ГОЭТАР-Медиа, 2016
  44. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis. 2020 Aug 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan
  45. Yuan YD, Gong XW, Yang YH. Meta-analysis of risk factors for recurrent pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2012;92(34):2419-25
  46. Leslom AN, Alrawiah ZMS, Al-Asmari AMA at al. Prevalence of pulmonary thromboembolism in nephrotic syndrome patients: A systematic review and meta- analysis. J Family Med Prim Care 2020;9(2):497-501. doi: 10.4103/jfmpc.jfmpc_1076_19
  47. Li SJ, Tu YM, Zhou CS, Zhang LH, Liu ZH. Risk factors of venous thromboembolism in focal segmental glomerulosclerosis with nephrotic syndrome. Clin Exp Nephrol 2016;20(2):212-7. doi: 10.1007/s10157-015-1149-4
  48. Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine in patients with steroidresistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999;56(6):2220-6. doi: 10.1046/j.1523- 1755.1999.00778.x
  49. Ramachandran R, Kumar V, Rathi M et al. Tacrolimus therapy in adult-onset steroid- resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. Nephrol Dial Transplant 2014;29(10):1918-24. doi: 10.1093/ndt/gfu097
  50. Meyrier A, Noel LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 1994;45(5):1446-56. doi: 10.1038/ki.1994.189
  51. Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 1991;35 Suppl 1:S37-42
  52. Ghiggeri GM, Catarsi P, Scolari F et al. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther 2004;26(9):1411-8. doi: 10.1016/j.clinthera.2004.09.012
  53. Segarra A, Vila J, Pou L et al. Combined therapy of tacrolimus and corticosteroids in cyclosporinresistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002;17(4):655- 62. doi: 10.1093/ndt/17.4.655
  54. Ramachandran R, Kumar V, Rathi M et al. Tacrolimus therapy in adult-onset steroid- resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. Nephrol Dial Transplant 2014;29(10):1918-24. doi: 10.1093/ndt/gfu097
  55. Gulati F, Sinha F, Gupta F et al. Treatment with tacrolimus and prednisolone ispreferable to intravenous cyclophosphamide as the initial therapy for children with steroid- resistantnephrotic syndrome. Кidney International 2012;82:1130-1135. doi:10.1038/ki.2012.238
  56. Gyamlani G, Molnar MZ, Lu JL et al. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrology Dialysis Transplantation 2017;32(1):157-164. doi: 10.1093/ndt/gfw227
  57. Laurin LP, Nachman PH, Foster BJ. Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis of the Literature. Can J Kidney Health Dis 2017;4:2054358117692559. doi: 10.1177/2054358117692559
  58. Chiou Y-Y, Lee Y-C, Chen M-J. Cyclosporine-based immunosuppressive therapy for patients with steroid-resistant focal segmental glomerulosclerosis: a meta-analysis. Curr Med Res Opin 2017;33(8):1389-1399. doi: 10.1080/03007995.2017.1322567
  59. Sprangers B, Meijers B, Appel G. FSGS: Diagnosis and Diagnostic Work-Up. Biomed Res Int 2016;4632768. doi: 10.1155/2016/4632768
  60. Thomas DB. Focal segmental glomerulosclerosis: a morphologic diagnosis in evolution. Arch Pathol Lab Med 2009;133(2):217-23
  61. Fuiano G, Comi N, Magri P et al. Serial morphometric analysis of sclerotic lesions in primary "focal" segmental glomerulosclerosis. J Am Soc Nephrol 1996;7(1):49-55
  62. Schwartz MM, Korbet SM. Primary focal segmental glomerulosclerosis: pathology, histological variants, and pathogenesis. Am J Kidney Dis 1993;22(6):874-83
  63. Sadowski CE, Lovric S, Ashraf S et al. A single-gene cause in 29.5% of cases of steroid- resistant nephrotic syndrome. J Am Soc Nephrol 2015;26(6):1279-89. doi: 10.1681/ASN.2014050489
  64. Lu L, Wan H, Yin Y et al. The p.R229Q variant of the NPHS2 (podocin) gene in focal segmental glomerulosclerosis and steroid-resistant nephrotic syndrome: a meta-analysis. Int Urol Nephrol 2014;46(7):1383-93. doi: 10.1007/s11255-014-0676-3
  65. Korbet SM. Treatment of primary FSGS in adults. J Am Soc Nephrol 2012;23(11):1769- 76. doi: 10.1681/ASN.2012040389
  66. Xie X, Liu Y, Perkovic V et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis 2016;67(5):728-741
  67. Geng DF, Sun WF, Yang L et al. Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials. J Renin Angiotensin Aldosterone Syst 2014;15(1):44-51. doi: 10.1177/1470320312474054
  68. Medjeral-Thomas N, Ziaj S, Condon M et al. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol 2014; 9(3):478-83. doi: 10.2215/CJN.07190713
  69. Ha JT, Neuen BL, Cheng LP et al. Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2019;171(3):181-189. doi: 10.7326/M19-0087
  70. Chen HY, Ou SH, Huang CW et al. Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis. Clin Drug Investig 2021;41(4):341-351. doi: 10.1007/s40261-021-01016-7
  71. Troyanov S, Wall CA, Miller JA et al. Focal and Segmental Glomerulosclerosis: Definition and Relevance of a Partial Remission. J Am Soc Nephrol 2005;16(4):1061-8. doi: 10.1681/ASN.2004070593
  72. Goumenos DS, Tsagalis G, El Nahas AM et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron Clin Pract 2006;104(2):c75-82. doi: 10.1159/000093993
  73. Pei Y, Cattran D, Delmore T et al. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am J Med 1987;82(5):938-44. doi: 10.1016/0002-9343(87)90155-0
  74. Schwartz MM, Evans J, Bain R, Korbet SM. Focal segmental glomerulosclerosis: prognostic implications of the cellular lesion. J Am Soc Nephrol 1999;10(9):1900-7
  75. Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994;23(6):773-83. doi: 10.1016/s0272-6386(12)80128-4
  76. Ponticelli C, Villa M, Banfi G et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999;34(4):618-625
  77. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998;32(1):72-9
  78. Banfi G, Moriggi M, Sabadini E et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991;36(2):53-9
  79. Pokhariyal S, Gulati S, Prasad N et al. Duration of optimal therapy for idiopathic focal segmental glomerulosclerosis. J Nephrol 2003;16(5):691-6
  80. Braun N, Schmutzler F, Lange C et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev 2008;2008(3):CD003233. doi: 10.1002/14651858.CD003233.pub2
  81. Chávez-Mendoza CA, Niño-Cruz JA, Correa-Rotter R et al. Calcineurin Inhibitors With Reduced-Dose Steroids as First-Line Therapy for Focal Segmental Glomerulosclerosis. Kidney Int Rep 2018;4(1):40-47. doi: 10.1016/j.ekir.2018.08.010
  82. Duncan N, Dhaygude A, Owen J et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004;19(12):3062-7. doi: 10.1093/ndt/gfh536
  83. Jiang X, Shen W, Xu X et al. Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies. Clin Exp Nephrol 2018;22(3):562-569. doi: 10.1007/s10157-017-1484-8
  84. Li HY, Zhang X, Zhou T et al. Efficacy and safety of cyclosporine a for patients with steroid-resistant nephrotic syndrome: a meta-analysis. BMC Nephrol 2019;20(1):384. doi: 10.1186/s12882-019-1575-8
  85. Ponticelli C, Rizzoni G, Edefonti A et al. A randomized trial of cyclosporine in steroid- resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-1384
  86. Bhaumik SK, Majumdar A, Barman SC. Comparison of pulse methylprednisolone vs cyclosporin based therapy in steroid resistant focal segmental glomerulosclerosis [abstract]. Indian Journal of Nephrology 2002;12
  87. Heering P, Braun N, Mullejans R et al. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004;43(1):10-8. doi: 10.1053/j.ajkd.2003.09.027
  88. El-Husseini A, El-Basuony F, Mahmoud I et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant 2005;20:2433-2438
  89. Ponticelli C, Edefonti A, Ghio L et al. Cyclosporin versus cyclophosphamide for patients with steroiddependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 1993;8:1326-1332
  90. Gipson DS, Trachtman H, Kaskel FJ et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011;80(8):868-78. doi: 10.1038/ki.2011.195
  91. Nayagam LS, Ganguli A, Rathi M et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrology Dialysis Transplantation 2008;23(6):1926-1930. doi: 10.1093/ndt/gfm538
  92. Choi MJ, Eustace JA, Gimenez LF et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61(3):1098-114. doi: 10.1046/j.1523- 1755.2002.00214.x
  93. Cattran DC, Wang MM, Appel G et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004;62(6):405-11. doi: 10.5414/cnp62405
  94. Geary DF, Farine M, Thorner P, Baumal R. Response to cyclophosphamide in steroid- resistant focal segmental glomerulosclerosis: a reappraisal. Clinical Nephrology 1984;22(3):109-113
  95. Martinelli R, Pereira LJ, Silva OMM et al. Cyclophosphamide in the treatment of focal segmental glomerulosclerosis. Braz J Med Biol Res 2004;37(9):1365-72.doi: 10.1590/s0100-879x2004000900011
  96. Ren H, Shen P, Li X et al. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. Am J Nephrol. 2013;37(1):84-90
  97. Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis. BMC Nephrol 2020;21(1):134. doi: 10.1186/s12882-020-01797-7
  98. Fernandez-Fresnedo G, Segarra A, González E et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009;4(8):1317-23. doi: 10.2215/CJN.00570109
  99. Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines – application to the individual patient. Kidney Int 2012;82(8):840-856
  100. Sandoval D, Poveda R, Draibe J et al. Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome. Clin Kidney J 2017;10(5):632-638
  101. Cheng X et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. Clinical Kidney Journal 2021;14(4):1042-1054
  102. Chitalia VC, Wells JE, Robson RA et al. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 1999;56(6):2236-42
  103. Wehrmann M, Bohle A, Held H et al. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990;33(3):115-122
  104. Laurin LP, Gasim AM, Derebail VK et al. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. Clin J Am Soc Nephrol 2016;11(10):1752-1759

  1. Deegens JK, Assmann KJ, Steenbergen EJ et al. Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? Neth J Med 2005;63(10):393-8
  2. Beaman M, Howie AJ, Hardwicke J et al. The glomerular tip lesion: a steroid responsive nephrotic syndrome. Clin Nephrol 1987;27(5):217-21

Для продолжения работы требуется вход / регистрация